臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"jia horng kao"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 441-490 / 1180 (共24頁)
<< < 4 5 6 7 8 9 10 11 12 13 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2021-09-04T06:11:37Z	Triple therapy for hepatitis C virus infection in patients receiving hemodialysis	Liu C.-H.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:36Z	Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: Molecular mechanisms and clinical significance	Yang H.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:36Z	Risk stratification of HBV infection in Asia-Pacific region	JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:36Z	The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo	Lin S.-R.; Yang H.-C.; Kuo Y.-T.; Liu C.-J.; Yang T.-Y.; Sung K.-C.; Lin Y.-Y.; Wang H.-Y.; Wang C.-C.; Shen Y.-C.; Wu F.-Y.; JIA-HORNG KAO; Chen D.-S.; Chen P.-J.
臺大學術典藏	2021-09-04T06:11:35Z	What can we learn from hepatitis B virus clinical cohorts?	Lin C.-L.; Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:35Z	Hepatitis B virus infection and metabolic syndrome: Fact or fiction?	Wang C.-C.; Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:35Z	Asunaprevir-containing regimens for the treatment of hepatitis C virus infection	Yang S.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:34Z	Viral hepatitis: HBV cure-can we pin our hopes on immunotherapy?	Yang H.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:34Z	Treating immune-tolerant Hepatitis B	Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:34Z	Micro-evolution of the hepatitis B virus genome in hepatitis B e-antigen-positive carriers: Comparison of genotypes B and C at various immune stages	Liu C.-J.; Chen T.-C.; Chen P.-J.; Wang H.-Y.; Tseng T.-C.; Cheng H.-R.; Liu C.-H.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:33Z	Hepatitis B virus genotypes and variants	Lin C.-L.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:33Z	Hepatitis B vaccination and prevention of hepatocellular carcinoma	JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:33Z	Reimbursement policies in the Asia-Pacific for chronic hepatitis B	Lim S.G.; Amarapurkar D.N.; Chan H.L.-Y.; Crawford D.H.; Gane E.J.; Han K.-H.; Ahn S.H.; Jafri W.; Jia J.; JIA-HORNG KAO; Lesmana L.A.; Lesmana C.R.A.; Mohamed R.; Phiet P.H.; Piratvisuth T.; Sarin S.K.; Sollarno J.D.; Eguchi Y.; Mahtab M.-A.; Lee K.H.
臺大學術典藏	2021-09-04T06:11:32Z	Serum biomarkers predictive of significant fibrosis and cirrhosis in chronic hepatitis B	Lin C.-L.; Liu C.-H.; Wang C.-C.; Liang C.-C.; Su T.-H.; Liu C.-J.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:32Z	Slow decline of hepatitis B burden in general population: Results from a population-based survey and longitudinal follow-up study in Taiwan	Chen C.-L.; Yang J.-Y.; Lin S.-F.; Sun C.-A.; Bai C.-H.; You S.-L.; Chen C.-J.; JIA-HORNG KAO; Chen P.-J.; Chen D.-S.
臺大學術典藏	2021-09-04T06:11:31Z	On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy	Huang Y.-W.; Takahashi S.; Tsuge M.; Chen C.-L.; Wang T.-C.; Abe H.; Hu J.-T.; Chen D.-S.; Yang S.-S.; Chayama K.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:31Z	Perspectives and control of hepatitis B virus infection in Taiwan	Lin C.-L.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:31Z	Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients	Wang C.-C.; Liu C.-H.; Lin C.-L.; Wang P.-C.; Tseng T.-C.; Lin H.H.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:30Z	Reply to: Modulation of Toll-like receptor 9 expression on monocytes of viral hepatitis patients	Huang Y.-W.; Yang S.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:30Z	Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir	Chen G.-Y.; Su T.-H.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:30Z	Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection	Cheng H.-R.; JIA-HORNG KAO; Wu H.-L.; Tseng T.-C.; Liu C.-H.; Yang H.-C.; Su T.-H.; Chen P.-J.; Chen D.-S.; Liu C.-J.
臺大學術典藏	2021-09-04T06:11:29Z	New insights into the evolutionary rate of hepatitis B virus at different biological scales	Lin Y.-Y.; Liu C.; Chien W.-H.; Wu L.-L.; Tao Y.; Wu D.; Lu X.; Hsieh C.-H.; Chen P.-J.; Wang H.-Y.; JIA-HORNG KAO; Chen D.-S.
臺大學術典藏	2021-09-04T06:11:29Z	Treating Immune-tolerant Hepatitis B	Tseng, T.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:29Z	Improving clinical outcomes of chronic hepatitis B virus infection	Su T.-H.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:28Z	Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection	Song L.-W.; Liu P.-G.; Liu C.-J.; Zhang T.-Y.; Cheng X.-D.; Wu H.-L.; Yang H.-C.; Hao X.-K.; Yuan Q.; Zhang J.; JIA-HORNG KAO; Chen D.-S.; Chen P.-J.; Xia N.-S.
臺大學術典藏	2021-09-04T06:11:28Z	Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection	Hsu C.-S.; Liu W.-L.; Chao Y.-C.; Lin H.H.; Tseng T.-C.; Wang C.-C.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:28Z	HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients	Peng C.-Y.; Hsieh T.-C.; Hsieh T.-Y.; Tseng K.-C.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Lin H.H.; Wang C.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:27Z	Comparison of abbott realtime HCV genotype II with versant line probe assay 2.0 for hepatitis C virus genotyping	Liu C.-H.; Liang C.-C.; Liu C.-J.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:27Z	Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy	Liang C.-C.; Liu C.-H.; Chung C.-S.; Lin C.-K.; Su T.-H.; Yang H.-C.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:27Z	Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection	Tseng T.-C.; Liu C.-J.; Chen C.-L.; Yang W.-T.; Yang H.-C.; Su T.-H.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:26Z	Predicting hepatitis B virus (HBV) surface antigen seroclearance in HBV e antigen-negative patients with chronic hepatitis B: External validation of a scoring system	Liu J.; Tseng T.-C.; Yang H.-I.; Lee M.-H.; Batrla-Utermann R.; Jen C.-L.; Lu S.-N.; Wang L.-Y.; You S.-L.; Chen P.-J.; Chen C.-J.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:26Z	Systematic review: Impact of interferon-based therapy on HCV-related hepatocellular carcinoma	Hsu C.-S.; Chao Y.-C.; Lin H.H.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:25Z	Peginterferon plus weight-based ribavirin for treatment-na?ve hepatitis C virus genotype 2 patients not achieving rapid virologic response: A randomized trial	Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; JIA-HORNG KAO; Yu M.-L.
臺大學術典藏	2021-09-04T06:11:25Z	Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial	Buti M.; Flisiak R.; JIA-HORNG KAO; Chuang W.-L.; Streinu-Cercel A.; Tabak F.; Calistru P.; Goeser T.; Rasenack J.; Horban A.; Davis G.L.; Alberti A.; Mazzella G.; Pol S.; Orsenigo R.; Brass C.
臺大學術典藏	2021-09-04T06:11:25Z	Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition	Su T.-H.; Shiau C.-W.; Jao P.; Liu C.-H.; Liu C.-J.; Tai W.-T.; Jeng Y.-M.; Yang H.-C.; Tseng T.-C.; Huang H.-P.; Cheng H.-R.; Chen P.-J.; Chen K.-F.; JIA-HORNG KAO; Chen D.-S.
臺大學術典藏	2021-09-04T06:11:24Z	Towards an HBV cure: State-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure	Zeisel M.B.; Lucifora J.; Mason W.S.; Sureau C.; Beck J.; Levrero M.; Kann M.; Knolle P.A.; Benkirane M.; Durantel D.; Michel M.-L.; Autran B.; Cosset F.-L.; Strick-Marchand H.; Tr?po C.; JIA-HORNG KAO; Carrat F.; Lacombe K.; Schinazi R.F.; Barr?-Sinoussi F.; Delfraissy J.-F.; Zoulim F.
臺大學術典藏	2021-09-04T06:11:24Z	A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan	Bennett H.; Waser N.; Johnston K.; JIA-HORNG KAO; Lim Y.-S.; Duan Z.-P.; Lee Y.-J.; Wei L.; Chen C.-J.; Sievert W.; Yuan Y.; Li H.
臺大學術典藏	2021-09-04T06:11:23Z	Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: A nation-wide cohort study	Huang Y.-W.; Wang T.-C.; Yang S.-S.; Lin S.-Y.; Fu S.-C.; Hu J.-T.; Liu C.-J.; JIA-HORNG KAO; Chen D.-S.
臺大學術典藏	2021-09-04T06:11:23Z	Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial	Liu C.-H.; Liu C.-J.; Huang C.-F.; Lin J.-W.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Lee C.-Y.; Chen S.-I.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:23Z	Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers	Tseng T.-C.; Liu C.-J.; Yang H.-C.; Chen C.-L.; Yang W.-T.; Tsai C.-S.; Kuo S.F.-T.; Verbree F.C.; Su T.-H.; Wang C.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:22Z	Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Na?ve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial	Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; JIA-HORNG KAO; Yu M.-L.
臺大學術典藏	2021-09-04T06:11:22Z	Artificial ascites is feasible and effective for difficult-to-ablate hepatocellular carcinoma	Wang C.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:21Z	Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naive Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study	Liu C.-H.; Sheng W.-H.; Sun H.-Y.; Hsieh S.-M.; Lo Y.-C.; Liu C.-J.; Su T.-H.; Yang H.-C.; Liu W.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:21Z	Looking into the crystal ball: biomarkers for outcomes of HBV infection	Yang H.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:21Z	Hepatitis B virus: New therapeutic perspectives	Lin C.-L.; Yang H.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:21Z	Can noninvasive biomarkers replace liver biopsy for chronic hepatitis B?	Lin C.-L.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:20Z	Characterization of metastatic tumor antigen 1 and its interaction with hepatitis B virus X protein in NF-κB signaling and tumor progression in a woodchuck hepatocellular carcinoma model	Li Y.-T.; Liu C.-J.; Su T.-H.; Cheng H.-R.; Jeng Y.-M.; Lin H.-L.; Wang C.-C.; JIA-HORNG KAO; Chen P.-J.; Chen D.-S.; Wu H.-L.
臺大學術典藏	2021-09-04T06:11:20Z	Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis	Yang H.-I.; Tseng T.-C.; Liu J.; Lee M.-H.; Liu C.-J.; Su T.-H.; Batrla-Utermann R.; Chan H.L.Y.; JIA-HORNG KAO; Chen C.-J.
臺大學術典藏	2021-09-04T06:11:19Z	HIV/HCV coinfection in Taiwan	Hsu C.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:19Z	Hepatocellular carcinoma recurrence after interferon-free direct acting antiviral treatment for chronic hepatitis C virus infection: Fact or fiction?	Liu C.-H.; JIA-HORNG KAO

顯示項目 441-490 / 1180 (共24頁)
<< < 4 5 6 7 8 9 10 11 12 13 > >>
每頁顯示[10|25|50]項目

	English \| 正體中文 \| 简体中文 \| 總筆數 :0
	造訪人次 : 51509778 線上人數 : 1143 教育部委託研究計畫計畫執行:國立臺灣大學圖書館